Stephen English – “The successful application of carbon isotopes in preclinical and clinical pharmaceutical research”
Friday, 2nd October 2015
International Isotope Society-Central European Division
21st Workshop on the Synthesis and Applications of Isotopes and Isotopically Labelled Compounds
Bad Soden, Germany
Surveying the Boundaries of Accelerator Mass Spectrometry: The Widening Scope of an Evolving Technology
Read the presentation
Go here to download speaker presentations, listen to and watch a recording of the presentations or read our comprehensive Q&A
Our concise two-pager was written by our AMS engineer Eric Guarin
Download How AMS Detection Works
Successful clinical 14C microtracer investigations: What can contemporary AMS do for you?
Expertise enables new AMS applications, Xceleron grows analytical operations
(Germantown, MD, USA; January 26, 2015) –Xceleron, a leader in the use of microtracers and Accelerator Mass Spectrometry (AMS) in novel life sciences investigations, has announced that it is retaining the consulting services of Graham Lappin (Visiting Professor of Pharmacology at the University of Lincoln, UK). Professor Lappin will advise the company and its customers on the application of microtracers in drug target research, clinical development and new non-pharmaceutical applications.
Professor Lappin has a long history and deep connections with the company going back to its early days. He also played an important role during Xceleron’s growth from a research-oriented laboratory in the UK to present-day in the US where it develops robust fit-for-purpose analytical methodology associated with AMS.
“Our relationship with Graham is important at this time for Xceleron” said Dr Michael Butler, CEO of Xceleron. “We have established a reputation for delivering representative, accurate and precise analytical data using AMS detection. This has been achieved by hiring accomplished analytical chemists who can develop and validate robust analytical methods around AMS. We are now turning the company’s full-time resources to scaling-up that service. Graham will help us customize our approach to novel cost-efficient clinical investigations and to continue applying our analytical expertise in new areas of drug research and non-pharmaceutical product development”
We are pleased to announce a new partnership between Xceleron and biopharmaceutics technology leader Molecular Profiles.
The alliance aims to simplify biopharmaceutics decisions using technology and efficient design of clinical investigations. Molecular Profiles has developed a unique Molecular Profiles Roadmap to investigate, evaluate and recommend a formulation development pathway that is the best option based on science. Xceleron has developed a scientifically superior approach to determining clinical drug disposition using LC + AMS. Together we can satisfy a real market need for science and technology to efficiently help with clinical biopharmaceutics decisions.
We look forward to a very active relationship with Molecular Profiles along the lines of that established with JCL.
In a recent publication in the Journal of Clinical Pharmacology, GSK have published data on the use of [14C] labelled IV microtracer for the determination of absolute bioavailability of dabrafenib in oncology patients. This is the first time that the use of this approach in patients has been published, and it demonstrates the value of the technique for gaining a greater understanding of the fundamental pharmacokinetics. Furthermore, by using this approach GSK were able to shorten the study time frame and it allowed for simultaneous collection of IV and oral pharmacokinetic parameters, thus reducing variability.
Particularly where patients as clinical research participants are concerned, IV microtracer studies offer an innovative and efficient approach for assessing absolute bioavailability and may be applied across a range of therapeutic areas and compound classes.
For further information on this paper and a copy of the abstract, please follow this link
For more information on how this approach can be used in drug development, please do not hesitate to contact Xceleron by email:
Xceleron is pleased to announce that they will be presenting 2 posters in collaboration with Incyte Corp and Neurocrine Biosciences Inc at the forthcoming AAPS Annual Meeting and Exposition to be held in Henry B. Gonzalez Convention Center, San Antonio, from 10th – 14th November 2013.
The Incyte poster (Application of Accelerator Mass Spectrometry in Early Clinical Development; #R6343) describes the use of Accelerator Mass Spectrometry (AMS) for the timely identification of 2 human metabolites that would have been neglected if simple qualitaTIVE LC/MS peak analysis had been used, thus allowing early identification of major metabolites and an early assessment of safety margins in accordance with FDA MIST and ICH M3 regulatory guidance. This poster will be presented between 08:30-11:30 on Thu 14 Nov.
The Neurocrine poster (Confirmation of the Selectivity of an LC+AMS Assay by Cross-Validation with LC MS/MS; Poster #M1360) describes a novel approach to validating the selectivity of LC+AMS by cross validation with a selective LC-MS/MS assay.
Copies of these posters can now be downloaded from our Resources page by clicking on this link.
Xceleron giving Plenary Lecture at 21st Annual IIS-CED Workshop, Bad Soden Germany, 2nd October
"...AMS [is] an invaluable tool in our early drug development program, allowing us to quickly assess bioavailability in humans and focus resources on our most promising drug candidates going forward."
Find out how we can help you accelerate your drug-development program.